Exicure (XCUR) Preferred Stock Liabilities (2016)

Exicure (XCUR) reported Preferred Stock Liabilities of $201000.0 for Q4 2016.

Exicure (XCUR) Preferred Stock Liabilities (2016) Analysis & Trends

Exicure has reported Preferred Stock Liabilities for 1 years, with the latest figure at $201000.0 in Q4 2016.

For the quarter ending Q4 2016, Preferred Stock Liabilities changed N/A year-over-year to $201000.0; the trailing twelve-month figure through Dec 2016 stood at $201000.0 (changed N/A YoY), and the FY2016 full-year result was $201000.0, changed N/A from the prior year.
Preferred Stock Liabilities for Q4 2016 stood at $201000.0.
The five-year high for Preferred Stock Liabilities was $201000.0 in Q4 2016, with the low at $201000.0 in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	-
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Exicure	19.38 Mn	16.77 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2016	201,000.00